Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Eicoman,
Regarding the comment regarding the low price..... It is hard for me to understand the justification for APRI being this low. The most comparable product opportunity was BPAX and Libigel.
Their testosterone topical product was not effective, which from a pharmacological perspective should not be a surprise. However, they did get to a Phase 3 level of study with the FDA, the stock was between $12-15 during these studies. With Femprox, I would expect the same opportunity for profit and the product actually has logic going for it from a clinical and pharmacological perspective.
We'll see once we get approval for Phase 3.
RVL
Eicoman,
The U.S. Phase 2 trial for Femprox has been completed with FDA correct?
Are we waiting for analysis of efficacy and side effects and a decision IF There should be a Phase 3 trial OR are we merely waiting for the FDA to provide guidance around the necessary parameters for a Phase 3 trial that might lead to FDA approval?
RVL
Just out on PR news wire
RVL
Apricus Biosciences Inc. Research Report
On June 10, 2013, Apricus Biosciences Inc. (Apricus Bio) announced that its marketing application for Vitaros, indicated for the treatment of patients with erectile dysfunction (ED), has been approved through the European Decentralized Procedure (DCP). Commenting on the approval, Richard Pascoe, Chief Executive Officer of Apricus Bio, said, "With its rapid onset of action and unique topical delivery, we believe that Vitaros will capture a significant share of the approximately $1 billion PDE-5 inhibitor market in Europe once it is launched by our commercial partners." Under the DCP, the Company filed its application for marketing approval designating Netherlands as the Reference Member State (RMS) on behalf of nine other European Concerned Member States (CMS) participating in the procedure. The CMS include France, Germany, Italy, UK, Ireland, Spain, Sweden, Belgium, and Luxembourg. Apricus Bio will continue to work independently as well as with its commercialization partners, Sandoz, Takeda, and Bracco for the next step of obtaining national phase approvals in order to make Vitaros ready to launch in each of the included territories across Europe. The Full Research Report on Apricus Biosciences Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/2aca_APRI]
Read more: http://www.nasdaq.com/article/new-research-grants-product-launches-and-positive-clinical-study-results---research-report-on-boston-scientific-cooper-arena-pharmaceuticals-apricus-biosciences-and-newlink-genetics-20130613-00230#ixzz2W6FRJTby
Kris_kade
Thanks for insight.
RVL
Does anyone have a copy of report that could be shared?RVL
Thanks
Thanks Eicoman.
Do you believe that the Confidentiality treatment is because of a pending good event or bad event?
Thanks
Eicoman,
Where is the ignore function on iHub?
RVL
Here we go, patient #1 in Angel trial.
RVL
Bioheart Announces First Patients Successfully Enrolled and Treated in ANGEL Trial
Bioheart, Inc. (OTCQB: BHRT) announced today that they have successfully enrolled and treated the first patients in the ANGEL Trial. The trial which is fully funded by Bioheart is being conducted in Mexico at the Hospital Angeles with the Regenerative Medicine Institute (RMI). This phase I ANGEL study will provide necessary safety and preliminary efficacy of adipose derived stem cells in patients with congestive heart failure.
Kristin Comella, Bioheart's Chief Science Officer, said, "This trial will provide important data for the field. We are thrilled to see brisk enrollment in the trial. Clearly there is a need for better therapies for this patient population and cell therapy offers a promising option."
Regarding #2....another scenario is that European approval would require more data for some reason & therefore APRI needs more $ and price per share will continue to flounder thru 2013
RV
Where, not on NASDAQ after hours?
RVL
DG
Could the Institution investor be Abbott? Or some other Big Pharma? (Similar to Fold GSK)
RVL
Does anyone have access to % Buy vs. Sell today?
Appears to be management, at the Board's direction
RVL
Kingme
Either you are correct, or management does not have confidence in Europe approval and are hedging their bet by raising $ before decision. I hope you are right.
RVL
Prospectus filed...Offering at $3.24?
See below?
RVL
"The number of shares of common stock shown above to be outstanding after this offering is based on the 30,354,715 shares outstanding as of March 31, 2013 and excludes the shares of common stock issuable upon exercise of the warrants being offered by us in this offering and excludes the following as of March 31, 2013:
•
2,756,187 shares of our common stock subject to options outstanding having a weighted average exercise price of $3.24 per share;
•
52,582 shares of our common stock subject to outstanding restricted stock units;
•
1,505,792 shares of our common stock subject to outstanding convertible debt;
•
1,874,583 shares of our common stock that have been reserved for issuance in connection with future grants under our stock option plans; and
•
3,205,492 shares of our common stock that have been reserved for issuance upon exercise of outstanding warrants having a weighted average exercise price of $4.56 per share.
If the underwriters’ over-allotment option is exercised in full, we will issue and sell an additional units and will have shares outstanding after the offering, excluding shares of common stock issuable upon exercise of the warrants offered hereby. Except as otherwise noted, all information in this prospectus supplement assumes no exercise of the underwriters’ over-allotment option."
DG,
Nicely done. Even just eyeballing data, it is apparent 200 line is wrong
Thanks for the constant vigilance for truth
RVL
Dimitrios George
Does the announcement of the removal of the poison pill open the door for a sale of Apricus ?
RVL
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 14, 2013
Apricus Biosciences, Inc.
(Exact name of registrant as specified in its charter)
Nevada 0-22245 87-0449967
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)
11975 El Camino Real, Suite 300, San Diego, CA 92130
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (858) 222-8041
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01. Other Events.
On May 14, 2013, the Board of Directors of Apricus Biosciences, Inc. (the “Company”) voted to terminate the Company’s Shareholder Rights Agreement (i.e., its “poison pill”), dated as of March 22, 2011, by and between the Company and Wells Fargo Bank, N.A., as rights agent (the “Rights Agreement”). As a result of this decision, the Board approved an amendment to the Rights Agreement (the “Amendment”) that will have the effect of terminating the poison pill.
The Amendment has been sent to Wells Fargo, the Company’s transfer agent for signature. The Amendment, when fully executed, will change the definition of “Final Expiration Date” in the Rights Agreement such that the rights to purchase Series D Junior Participating Cumulative Preferred Stock issued pursuant to the Rights Agreement will expire and no longer remain outstanding as of 5:00 p.m. New York time on the date of execution.
Upon the expiration of these purchase rights, the Rights Agreement will expire and no longer be of any force or effect. The Company expects that the Amendment will be fully executed, and the Rights Agreement will terminate, on or before May 17, 2013. The text of the Amendment will be filed as an exhibit to a Current Report on Form 8-K following full execution of the Amendment.
The Rights Agreement is described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on March 24, 2011, and such description is incorporated herein by reference.
* * *
Got it. I intend to load up again today at these prices
Does anyone know what this "Notice of Effectiveness" means?
http://www.sec.gov/Archives/edgar/data/1388319/999999999513001417/9999999995-13-001417-index.htm
From 2007
DG &Gang,
FYI
I have attached "French" divestiture statement as recently reported to SEC. I am glad we are out of non- core businesses.
But, what will this do to APRI stock over the next few monts?
Opinions?
RVL
http://boardvote.com/symbol/APRI/communique/313378
Presentation was well done and clinical results are impressive. Also the physicians and hospitals and Academic medical centers using product is like Who's who.
Why doesn't this stock take off? Opinions?
Druides
Count ten and hope for this management team's success.
The product works. Unlike BioSante, Apricus' Vitaros actually has scientific merit. I am frustrated by past mistakes too. But, in the end the product works and we'll either be selling a product to the public or a company to sell to the public or at worst, the company will be sold.
RVL
The potential for OTC status for Vitaros with or without the condom dosage form is very real and differs greatly by country.
I have attached an excellent review that includes USA and EU individual markets.
To me the potential for OTC category in England, Germany, and France provides an understanding of the Big Pharma relationships.
When Vitaros starts being used in Canada, and if it gets approved in EU this stock will go through the roof.
Rvl
http://www.istanbul-ekonomi.com/en/yayinlar/Recetesiz%20ilac%20raporu_ENG.pdf
Am I correct that the sale of the building that closed in March will also be recognized in Q1?
Rvl
See below.
Item 2.01 Completion of Acquisition or Disposition of Assets.
On March 11, 2013, NexMed (U.S.A.), Inc. (“NexMed”), a wholly-owned subsidiary of Apricus Biosciences, Inc. (the “Company”) and Esrog LLC, a Jack Breitkopf company (the “Purchaser”) closed the transaction to sell the Company’s real property located at 89 Twin Rivers Drive and 113 Milford Road, East Windsor, NJ (the “Property”) for a total of $4.125 million.
As previously reported on a Current Report on Form 8-K filed by the Company on January 3, 2013, on December 28, 2012, NexMed entered into a Real Estate Purchase Agreement (the “Purchase Agreement”) with the Purchaser whereby the Company agreed to sell the Property. A copy of the Purchase Agreement will be filed as an exhibit to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012.
Eicoman,
Great find, study is Phase 2, 30 patients, completed by August.
Question: I assume this is with older version of Vitaros. Why would this be considered phase 2 & not phase 3?
Rvl
Gd
Yahoo finance has Quarterly finance report listed on March 13th, Ed Cox is presenting same day at Bio-Europe Spring meeting.
Any insight?
RVL
March 13th is date for quarterly report per yahoo finance
Rvl
Thanks kingme
DG,
I agree with you recent posts regarding PR & Phase 4 testing.
Three additional points:
1. I would postulate that vitaros in Canada will be an Abbvie product. Please take a look at announcement regarding Abbvie & Abbott split.
Http://www.sec.gov/Archives/edgar/data/1551152/000104746912006434/a2209760zex-99_1.htm
2. If there are Phase 4 studies in Canada, they are being conducted by Abbvie not Apricus. Therefore, PR is controlled by Abbvie & Abbvie has a lot going on right now, with positioning pipeline. When they do start discussing Vitaros in Canada, I think it is a small opportunity for them.
3. I am hoping / speculating that Abbvie is more interested in Femprox & the huge untapped opportunity for women. Abbott/Abbvie has proven that they believe in Nextact with Apricus/Canada deal and there is an array of potential existing drug products that Abbott/Abbvie have that could be used in Nextact topical dosage form.
Therefore, I believe the delay with Vitaros in Canada and the firing of Damaj is secondary to Abbvie separation from Abbott & Damaj' reluctance to sell Apricus. My thinking is the run up is secondary to the pending acquisition of Apricus by Abbvie NOT the numerous opportunities that we know are projected in 2013.
RVL
Phase 4 clinical trials are also a tactic to get physicians to prescribe a drug. Physicians are typically paid to conduct a clinical trial, plus they get exposed to a positive result. (Hopefully) this is a great tactic with drug product that physicians have little or no experience and/or have no reason to change current prescribing patterns
RVL
GD,
Any insight on Board member resignation significance?
RVL
The search for a CEO is being conducted by DavenportMajor.
A review of clients reveals Abbott has used this Search firm many times. Coincidence??http://www.davenportmajor.com/browse-68560/Latest-News.html
To all on this Board rather than posting how one "feels" and personal disputes about who is right about what you feel.
Why don't we share information.
Thank you Merlin..
Casino kid
Although I have followed this board for over a year, this my second post.
My first was in response to your accusing others of "spin".
This one is only to say you sure have opinions like someone who calls themselves "court fool" on another board.
But then he is a total outcast because of his obvious motives.
You aren't the same person are you?
Rvl